Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany;Kostenvergleich von insulin glargin mit insulin detemir im rahmen einer basis-bolus-behandlung (ICT) mit mahlzeitenbezogenem insulin aspart bei typ-2-diabetes in Deutschland

GMS German Medical Science

Volumn 8, Issue , 2010, Pages

  Pscherer, Stefan ^a   Dietrich, Eva Susanne ^b   Dippel, Franz Werner ^c   Neilson, Aileen Rae ^b  

^a Klinikum Traunstein   (Germany)

^b HealthEcon Ltd   (Switzerland)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Basal insulin; Cost analysis; Insulin detemir; Insulin glargine; Type 2 diabetes

Indexed keywords

EID: 84906738924     PISSN: 16123174     EISSN: None     Source Type: Journal    
DOI: 10.3205/000106     Document Type: Article

References (34)

1. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-totarget trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976-87. DOI: 10.1016/j.clinthera.2008.11.00 1
2. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia. 2008;51(3):408-16. DOI: 10.1007/s00125-007-0911-x
3. Pscherer S, Dietrich ES, Dippel FW, Neilson AR. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. Int J Clin Pharmacol Ther. 2010;48(2):129-37.
4. Guisasola A, Llorente C, Rubio-Terrés C. Cost analysis of type 2 diabetes mellitus treatment with glargine insulin or detemir insulin in Spain. Rev Esp Econ Salud. 2007;6(5):304-10.
5. Guisasola A, Llorente C, Rubio-Terrés C. Revisión del estudio "Análisis de costes del tratamiento de la diabetes mellitus de tipo 2 con insulin glargina e insulin detemir en España". Rev Esp Econ Salud. 2008;7(4):150-1.
6. Kósa J, Odhiambo R; Sanofi-aventis zRT. Költség-minimalzációs elemzés: A Lantus és a detemir bázisinzulinok összehasonlitása a diabetes aktuális terápiás gyakorlatában. Egészséggazdaságtan Farmakoökonómia. 2008;6:41-4.
7. Pichón-Riviere A, Caporale JE, Augustovski FA, von SchulzHausmann C, Gagliardino JJ. Cost comparison of insulin glargine and insulin detemir in type 2 diabetes mellitus in Argentina: A trial-based probabilistic model [Poster]. ISPOR 11th Annual European Congress, Athens 2008. Value Health. 2008;11(6):A506, PDB33. DOI: 10.1111/j.1524-4733.2008.00453_2.x
8. Evans M, Owens D, Carroll D, Keech M. Cost Savings in Type 2 Diabetes with Insulin Glargine Compared with Insulin Detemir in the UK. In: ADA 69th Scientific Sessions; June 5-9 2009; New Orleans, Louisiana. Alexandria, VA: American Diabetes Association; 2009. Abstract 2016-PO. Available from: http:// professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID= 74136
9. Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, Reed S, Rutten FFH, Sculpher M, Severns J. Transferability of Economic Evaluations Across Jurisdictions. ISPOR Good Research Practices Task Force Report. Value Health. 2009;12(4):409-18. DOI: 10.1111/j.1524-4733.2008.00489.x
10. Institute for Quality and Efficiency in HealthCare (IQWIG). Methods for Assessment of the Relation of Benefits to Costs in the Germany Statutory Healthcare System [Version 1. 1, 9.10.2008]. Cologne: Institute for Quality and Efficiency in HealthCare (IQWIG); 2008. Available from: http://www.iqwig.de/download/08-01-24_Draft_Methods_of_the_Relation_of_B enefits_to_Costs_ Version_1_0.pdf
11. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C; Hanover Consensus Group. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health. 2008;11(4):539-44. DOI: 10.1111/j.1524-4733.2007. 0030 1.x
12. Drummond MF, Sculper MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd edition. Oxford, New York: Oxford University Press; 2005.
13. Lauer-Taxe online. Online Pharmaceutical Database 2008. Fürth: Lauer-Fischer GmbH; 2010. Available from: http://www.lauerfischer. de/LF/Seiten/Produkte/Lauer-Taxe+online/Lauer-Taxe+ online-EN.aspx
14. Haas M. Pennadeln-Viele sparen am falschen Ende. Mainz: Initiative diabetes-world; 2007. Available from: http:// www.diabetes-world.net/Portal-fuer-Patienten-und-Interessierte/ Diabetes-behandeln/Insulininjektion.htm?ID=3367
15. Ypsomed GmbH (Höchster Straße 70, 65835 Liederbach). Liederbach: Ypsomed GmbH; 2010. Available from: http:// www.ypsomed.de
16. Florian Müller Gmbh-the friendly mail-order for diabetics (Wichmannstrasse 4, 22607Hamburg). Hamburg: Florian Müller GmbH. Available from: http://www.florian-mueller. de
17. Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T. Kosten für antihyperglykämische Arznei-und Verbrauchsmittel und Therapiezufriedenheit bei Typ-2-Diabetes [Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetesX]. Dtsch med Wochenschr. 2009;134:1207-13. DOI: 10.1055/s-0029-1222595
18. Swinnen SG, DeVries JH. Higher dose requirements with insulin detemir in type 2 diabetes--three cases and a review of the literature. Diabetes Res Clin Pract. 2009;84(2):e24-6. DOI: 10.1016/j.diabres.2009.02.009
19. Rossetti P, Porcellati F, Ricci NB, Candeloro P, Cioli P, Bolli GB, Fanelli CG. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes. 2008;57(3):746-56. DOI: 10.2337/db07-1433
20. Johnson CK, Shimshi M. When is a unit of insulin not a unit of insulin? Detemir dosing in type 2 diabetes. In: ADA 68th scientific sessions 2008; June 6-10, 2008; San Francisco, California. Alexandria, VA: American Diabetes Association; 2008. Abstract 8-LB. Available from: http://professional.diabetes.org/Abstracts_ Display.aspx?TYP=1&CID=70983
21. Dailey G, Admane K, Mercier F, Owens D. Comparing insulin glargine with insulin detemir-effects of a1c lowering on weight change and insulin dose in patients with type 2 diabetes. Diabetes. 2009;58(Suppl. 1): A128, Abstr. 480-P.
22. BKK-LKK-Partner-Apothekenvertrag. Bonn: HealthNetConsult GmbH; 2010. Available from: http://www.apothekenvertrag.de/ index.php?id=40
23. Hagenmeyer EG, Gothe H, Landgraf W, Kulik M, Schiffhorst G, Häussler B. Ressourcen-Inanaspruchnahme und Kosten der Behandlung von Typ-2-Diabetikern unter Insulin-glargin-oder Insulindetemir-Therapie (LIVE-KK): Analyse von KrankenkassenRoutinedaten mittels Propensity Score Matching [Comparison of Utilisation and Costs of Treatment for Patients with Type 2 Diabetes Using Insulin glargin or Insulin detemir: a Claims Data Analysis using the Propensity Score Matching Method]. Gesundh ökon Qual manag. 2010;15(3):121-6. DOI: 10.1055/s-0028-1110023
24. Dippel FW, Schneider T, Rosak C, Brüggenjürgen B. Behandlungskosten bei insulinpflichtigen Diabetikern unter Insulin glargin versus Insulindetemir-Ergebnisse einer repräsentativen Verordungsdatenanalyse. Perfusion. 2009;22(6):194-9.
25. Dixon S, Peters JR. Evaluating the 'real' cost-effectiveness of health technology: reconciling the public interest with patient interests. Curr Med Res Opin. 2007;23(s1):S1-S6. DOI: 10.1185/030079907X167552
26. Poole CD, Tetlow T, McEwan P, Holmes P, Currie CJ. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine clinical practice in the UK: a retrospective database analysis. Curr Med Res Opin. 2007; 23(s1):S41-S48. DOI: 10.1185/030079907X167589
27. Wiesner T, Schädlich PK, Dippel FW, Koltermann KC, Hagenmeyer EG. Insulin glargin versus Insulindetemir in der Basel-BolusBehandlung von Patienten mit Typ 1-Diabetes mellitus. Perfusion. 2010;23:56-65.
28. Bierwirth RA, Kohlmann T, Theobald KH, Holle, R, Landgraf W, on behalf of the LIVE-COM Study Group. Typ 2 diabetes lower costs of diabetes of care with insulin glargine compared to insulin detemir in type 2 patients treated with a basal bolus regime. Poster-Präsentation auf dem DDG Kongress 2009. Diabetol Stoffwechsel. 2009;4:81, Abstract 299.
29. IQWIG. Health Economic modelling. In: General Methods for the Assessment of the Relation of Benefits to Costs. Version 1.0-19/11/2009. Cologne: IQWIG; 2009. pp 25.
30. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trialbased economic evaluation for health care decision making? Health Econ. 2006;15(7):677-87. DOI: 10.1002/hec.1093
31. Lang DL, Lopert R, Hill SR. Use of pharmacoeconomics in prescribing research; part 5: modelling; beyond clinical trials. J Clin Pharm Ther. 2003;28(5):433-9. DOI: 10.1046/j.1365-2710.2003.00458.x
32. Minshall ME, Tunis SL, Sauriol L. Cost-effectiveness of insulin glargine compared to insulin detemir for type 1 and type 2 diabetes mellitus patients in the Canadian payer setting [Poster]. ISPOR 11th Annual European Congress, Athens 2008. Value Health. 2008;11(6):A502, PDB22. DOI: 10.1111/j.1524-4733.2008.00453_2.x
33. Tetlow AP. The relative cost effectiveness of insulin glargine versus detemir using UK real life data in patients with type 2 diabetes mellitus. In: 44th meeting of the European Association of Diabetes Rome; 7-11 September 2008; Rome, Italy. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx? sKey=22290bdf-8ef2-48bc-a123-560f27e368a1&cKey= 87db9feb-7b9b-4 1d6-9650-a9b7ee4cefe0&mKey={D4A66D7CBA0B-404F-9FDC-B8B6944A923D}
34. Levin PA, Danel A, Bromberger L, Choi JC, Mersey J. Glycemic control and cost-effectiveness following inititation of insulin glargine or detemir in patients with type 2 diabetes mellitus-an analysis of electronic medical records [Poster]. ISPOR 11th Annual European Congress, Athens 2008. Value Health. 2008;11(6):A496, PDB5. DOI: 10.1111/j.1524-4733.2008.00453_2.x